Henletor (torsemide) / Orchid - LARVOL DELTA

Harmless or Harmful? A Case Report on Pseudomelanosis Duodeni (ACG 2026) - "She reported adherence with her medications including carvedilol, hydralazine, torsemide, semaglutide, and ferrous sulfate...PD appears to occur predominantly in middle-age females and have a strong association with hypertension and diabetes mellitus and the use of certain medications such as hydralazine, ferrous sulfate, and sulfur-containing loop diuretics such as furosemide or torsemide...Therefore, the purpose of this case report is to bring awareness about PD and highlight the importance of distinguishing it from duodenal melanoma to avoid unnecessary work-up as it is benign and requires no further work-up or treatment. Figure: Abnormal mucosa in the duodenum"

Case report • Clinical • Cardiovascular • Congestive Heart Failure • Constipation • Diabetes • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hypertension • Melanoma • Metabolic Disorders • Solid Tumor

Proximal Splenic Artery Embolization for Refractory Post-Liver Transplant Ascites (ACG 2026) - "Postoperatively, he received tacrolimus and mycophenolate mofetil with infection prophylaxis...Torsemide was ineffective and discontinued due to worsening renal function...Figure: Figure 1A: Splenic artery angiography demonstrating splenic inflow. Figure: Figure 1B: Post-embolization image showing coil placement in the proximal splenic artery and obstructed distal arterial flow."

Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Fibrosis • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Portal Hypertension • Thrombosis • Transplantation • Type 2 Diabetes Mellitus

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=30 ➔ 0 | Initiation date: Dec 2025 ➔ May 2025 | Recruiting ➔ Withdrawn

Enrollment change • Trial initiation date • Trial withdrawal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Extended-release Torsemide To Improve Overactive Bladder Symptoms In Chronic Heart Failure: A Randomized, Double-blind, Crossover Pilot Study [Poster no. 664] (HFSA 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder

Torsemide Versus Furosemide in Heart Failure: A Systematic Review and Meta-analysis of 402,867 Patients [Poster no. 205] (HFSA 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Intrarenal Determinants of GFR Decline During Loop Diuretic Therapy. (PubMed, Hypertension) - "We propose that a passive, obstructive component of reduced renal blood flow combines with activation of renal afferent nerves, macula densa-derived renin release with intrarenal Ang II (angiotensin II) formation, and generation of vasoconstrictor prostaglandins and thromboxane to provide intrarenal mechanisms of passive and active increases in renal vascular resistance that together can reduce the glomerular filtration rate. The hypothesis that a reduction in the glomerular filtration rate with loop diuretics can derive from intrarenal mechanisms of vasoconstriction rather than from volume depletion suggests novel approaches to manage diuretic resistance and worsening renal function in heart failure."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Flood Syndrome Secondary to BuddâChiari Syndrome: A Case Report (ACG 2026) - "Prophylactic ceftriaxone, metronidazole were given and patient was optimized on a spironolactone and torsemide regimen to reduce ascitic fluid pressure. The patient was instructed on regular follow-up and strict compliance to her BCS regimen including rivaroxaban, carvedilol...This case expands the etiological spectrum of Flood syndrome and emphasizes that BCS should be considered as a potential cause in patients presenting with spontaneous umbilical ascitic leakage. Figure: Picture depicting the sinus tract on skin"

Case report • Clinical • Cardiovascular • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Portal Hypertension • Thrombosis

Torsemide vs Furosemide in Cirrhosis and Ascites: A Propensity-Matched Analysis Stratified by Spironolactone Use (ACG 2026) - "The overall matched cohort included 1,666 patients per group. Torsemide was associated with lower all-cause mortality at 30 days (16.4% vs 27.3%; HR 0.53, 95% CI 0.46-0.62), 90 days (24.8% vs 33.2%; HR 0.63, 95% CI 0.55-0.72), and 1 year (31.9% vs 40.2%; HR 0.66, 95% CI 0.59-0.75). Torsemide was also associated with lower hospitalization, paracentesis, ICU admission, and decompensation across all follow-up intervals with similar renal composite outcomes and hyponatremia."

Cardiovascular • Chronic Kidney Disease • Fibrosis • Heart Failure • Hepatology • Immunology • Peritoneal Cancer • Renal Disease

From Golden Berry To Golden Nanoprobe: Sustainable Fluorescent Sensing of Torsemide For Doping Control in Athletes. (PubMed, J Fluoresc) - "Greenness and blueness assessments using Complex-GAPI, BAGI (80), AGREE-Prep (0.79), and NAT (91) confirmed superior environmental sustainability and feasibility for on-site detection in doping regulation laboratories. This strategy offers a rapid, cost-effective, sensitive, and eco-friendly platform for anti-doping surveillance and therapeutic monitoring of TSD in biological matrices, guaranteeing fair competition and safeguarding athletes' health in the sports world."

Journal

In symptomatic HF, sacubitril-valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo. (PubMed, Ann Intern Med) - "GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text]."

Journal • Cardiovascular

Lost to Follow-Up in Pragmatic Trials With Remote Follow-Up: Insights From CONNECT-HF and TRANSFORM-HF. (PubMed, J Am Heart Assoc) - "In analyses of 2 pragmatic trials of patients hospitalized for HF in the United States, younger patients, those without implantable cardioverter-defibrillator/cardiac resynchronization therapy, and smaller hospital size were associated with higher LTFU. Tailoring retention strategies to both patient and site characteristics should be explored in future work to help mitigate LTFU in pragmatic trials."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: win-ratio reanalysis of the TRANSFORM-HF trial. (PubMed, Am Heart J) - P3 | "The overall WR comparison between torsemide and furosemide showed no statistically significant difference in the primary 12-month analysis. The WR framework provided an interpretive decomposition across outcome domains but did not establish superiority of either loop diuretic strategy. All findings should be considered exploratory."

HEOR • Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Severe Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia (BRASH) Syndrome Successfully Managed With Transvenous Pacing and Continuous Renal Replacement Therapy. (PubMed, Cureus) - "A 71-year-old male with stage IIIB chronic kidney disease (CKD), heart failure with improved ejection fraction, and coronary artery disease status post coronary artery bypass grafting, on carvedilol, losartan, and torsemide, was brought to the emergency room from a rehabilitation facility for a syncopal event and unresponsiveness. Prognosis depends largely on early recognition and prompt intervention. This case highlights a severe presentation of BRASH syndrome in which timely initiation of CRRT corrected the underlying metabolic derangements, and transvenous pacing provided temporary hemodynamic support, ultimately leading to clinical recovery."

Journal • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Critical care • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Diuretic Resistance Risk and the Efficacy of Torsemide vs Furosemide: A Post-Hoc Analysis of the TRANSFORM-HF Trial. (PubMed, Eur J Heart Fail) - "Among patients discharged after HF hospitalization, higher diuretic resistance risk, assessed by the BAN-ADHF score, is associated with higher risk of mortality, HF hospitalization, and worse quality-of-life. Diuretic resistance risk status did not modify the treatment effects of torsemide versus furosemide."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

When the TSH Rises: Hypothyroidism as a Clue to Inadequate Diuretic Response (ENDO 2026) - "She was initially treated with bumetanide, followed by a trial of torsemide, and subsequently transitioned to a combination of oral furosemide and metolazone due to persistent volume overload and inadequate diuretic response...Given her reported medication adherence, her profound hypothyroidism was attributed to impaired gastrointestinal absorption of levothyroxine in the setting of significant fluid overload and gut edema. This case highlights that persistent hypothyroidism in patients with decompensated heart failure may serve as an indirect marker of long-standing, refractory volume overload. TSH evaluation could potentially be a useful adjunct in assessing the duration and severity of diuretic resistance, particularly when compliance with thyroid replacement therapy is not in question."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Endocrine Disorders • Gout • Heart Failure • Hypotension • Inflammatory Arthritis • Nephrology • Renal Disease

Urine sodium concentration and diuretic responsiveness in dogs receiving orally administered loop diuretics for chronic congestive heart failure. (PubMed, J Vet Intern Med) - "Measurement of uNa and diuretic concentration identifies dogs with low natriuresis, which is not predicted by diuretic dose or duration. Observation of uNa patterns generates hypotheses regarding potential causes of low DR that warrant confirmation in larger studies."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Not All Pulmonary Vascular Dilations Are AVMs: A Case of Pulmonary Venous Varix in Pulmonary Hypertension (PHA 2026) - "He had completed a prolonged course of prednisone for sarcoidosis, which remained in remission with residual fibrotic changes...His home medications included ambrisentan, tadalafil, torsemide, and abiraterone...The distinction is increasingly relevant as emerging PAH therapies such as sotatercept, which modulates TGF ß signaling, may induce or unmask intrapulmonary shunts and are not suitable in patients with true AVMs... Multi-phase pulmonary angiography with careful evaluation of arterial and venous phases, combined with detailed review of cross-sectional imaging, remains essential for accurate diagnosis of pulmonary venous varix. Clinicians must maintain heightened awareness of this rare entity, especially in the context of pulmonary hypertension, to ensure appropriate conservative management. Figures/Images: Figure 1: CT chest angiography images; A and B - Sagittal and axial sections showing dilated tortuous vein crossing the major fissure."

Clinical • Cardiovascular • CNS Disorders • Fibrosis • Genito-urinary Cancer • Hypertension • Immunology • Prostate Cancer • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Solid Tumor • Varicose Veins

Efficacy of torsemide versus furosemide in heart failure: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Arch Med Sci Atheroscler Dis) - "There was no significant difference in weight change between the two diuretics (mean difference -0.15; 95% CI: -0.82-0.52; p = 0.66; I 2 = 94%). Furosemide and torsemide have similar impacts on mortality, hospitalization due to heart failure, and weight change in patients with congestive heart failure."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention. (PubMed, Front Oncol) - "Among these changes, the differentially abundant metabolites torsemide, cortolone-3-glucuronide, and trimethylselenonium all had area under the curve (AUC) values greater than 0.75 in distinguishing between different disease stages and chemotherapy statuses, demonstrating their good potential as biomarkers...The integrated multiomics model helps characterize the biological differences across various stages of breast disease. The identified characteristic bacterial genera and metabolite combinations provide preliminary theoretical clues for the future exploration of microbiome-related mechanisms in breast cancer and for auxiliary assessments."

Journal • Breast Cancer • Infectious Disease • Metabolic Disorders • Oncology • Solid Tumor

Decongestion in chronic heart failure. (PubMed, JRSM Cardiovasc Dis) - "Contemporary randomized data do not demonstrate superiority of torsemide over furosemide. Small trials and systematic reviews suggest that in carefully selected, stable, non-congested patients, diuretic withdrawal or reduction can be feasible, with ∼25-35% requiring re-initiation within 1-3 months and consistent lowering of renin activity; however, clinical outcome benefit remains unproven. Overall, evidence supports maintaining euvolemia with the lowest effective diuretic dose and considering monitored deprescribing in appropriate low-risk patients."

Journal • Review • Amyloidosis • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of loop diuretics for chronic heart failure: a systematic review and meta-analysis. (PubMed, Eur J Clin Pharmacol) - "The choice of loop diuretic did not seem to influence the risk of mortality. In a pooled analysis of torsemide and piretanide, the risk of SAEs was higher when compared to furosemide, but the certainty of this finding is limited. Azosemide was associated with weight loss compared to furosemide in one small trial."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Molecularly imprinted metal-organic framework-based potentiometric sensor for sensitive detection of torsemide in dietary supplements and milk. (PubMed, Food Chem) - "Results showed recoveries ranging from 97.91%-104.53% and RSDs below 1.7%. These findings affirm sensor's precision and suitability for routine screening of TOR adulteration in both dietary supplements and food matrices."

Journal

Unraveling the Enigma: Diagnostic Complexity in a Case of Idiopathic Membranoproliferative Glomerulonephritis (NKF-SCM 2026) - "At discharge, management involved oral steroids, mycophenolate, torsemide, spironolactone, and chlorthalidone. CONCLUSION Despite improved diagnostic capabilities, idiopathic MPGN remains an enigma. This case highlights the diagnostic complexity of such cases."

Clinical • Chronic Kidney Disease • Fibrosis • Glomerulonephritis • Hematological Malignancies • Hepatology • Immunology • Lupus Nephritis • Lymphoma • Mantle Cell Lymphoma • Nephrology • Pulmonary Disease • Renal Disease

Comprehensive guideline-directed medical therapy strategies on health status outcomes in patients with heart failure: the LAQUA-HF randomised clinical trial. (PubMed, Heart) - "This trial found no evidence of benefit of one treatment over another for health status over 6 months. Given the sample size and predefined power, modest differences between treatments cannot be excluded."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Torsemide and warfarin: A cautionary case of altered international normalized ratio and bleeding risk. (PubMed, Indian J Pharmacol) - "Torsemide was discontinued and replaced with furosemide, after which a gradual stabilization of INR levels was observed. This case highlights a potential interaction between warfarin and Torsemide resulting in elevated INR and increased bleeding risk. Clinicians should exercise caution and ensure close INR monitoring when initiating Torsemide in patients receiving warfarin therapy."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Mood Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus